Molecular classification of tamoxifen-resistant breast carcinomas by gene expression profiling.

PURPOSE To discover a set of markers predictive for the type of response to endocrine therapy with the antiestrogen tamoxifen using gene expression profiling. PATIENTS AND METHODS The study was performed on 112 estrogen receptor-positive primary breast carcinomas from patients with advanced disease and clearly defined types of response (ie, 52 patients with objective response v 60 patients with progressive disease) from start of first-line treatment with tamoxifen. Main clinical end points are the effects of therapy on tumor size and time until tumor progression (progression-free survival [PFS]). RNA isolated from tumor samples was amplified and hybridized to 18,000 human cDNA microarrays. RESULTS Using a training set of 46 breast tumors, 81 genes were found to be differentially expressed (P < or = .05) between tamoxifen-responsive and -resistant tumors. These genes were involved in estrogen action, apoptosis, extracellular matrix formation, and immune response. From the 81 genes, a predictive signature of 44 genes was extracted and validated on an independent set of 66 tumors. This 44-gene signature is significantly superior (odds ratio, 3.16; 95% CI, 1.10 to 9.11; P = .03) to traditional predictive factors in univariate analysis and also significantly related with a longer PFS in univariate (hazard ratio, 0.54; 95% CI, 0.31 to 0.94; P = .03) as well as in multivariate analyses (P = .03). CONCLUSION Our data show that gene expression profiling can be used to discriminate between breast cancer patients with progressive disease and objective response to tamoxifen. Additional studies are needed to confirm if the predictive signature might allow identification of individual patients who could benefit from other (adjuvant) endocrine therapies.

[1]  Norman Wolmark,et al.  Multi-gene Rt-pcr assay for predicting recurrence in node negative breast cancer patients-nsabp studies B-20 and B-14 , 2003 .

[2]  M. Ringnér,et al.  Impact of DNA amplification on gene expression patterns in breast cancer. , 2002, Cancer research.

[3]  R. Tibshirani,et al.  Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[4]  S. Mandlekar,et al.  Mechanisms of tamoxifen-induced apoptosis , 2001, Apoptosis.

[5]  Syed Mohsin,et al.  Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer , 2003, The Lancet.

[6]  V. Jordan,et al.  Tamoxifen: a most unlikely pioneering medicine , 2003, Nature Reviews Drug Discovery.

[7]  C. Cropp,et al.  Candidate target genes for loss of heterozygosity on human chromosome 17q21 , 2004, British Journal of Cancer.

[8]  C. Iacobuzio-Donahue,et al.  The desmoplastic response to infiltrating breast carcinoma: gene expression at the site of primary invasion and implications for comparisons between tumor types. , 2002, Cancer research.

[9]  R. Rubens,et al.  Assessment of response to therapy in advanced breast cancer. A project of the programme on clinical oncology of the International Union against Cancer, Geneva, Switzerland , 1977, European journal of cancer.

[10]  Yudong D. He,et al.  A Gene-Expression Signature as a Predictor of Survival in Breast Cancer , 2002 .

[11]  Allison Jones,et al.  cDNA microarray analysis of genes associated with ERBB2 (HER2/neu) overexpression in human mammary luminal epithelial cells , 2003, Oncogene.

[12]  C. McLaren,et al.  Association between in vitro platinum resistance in the EDR assay and clinical outcomes for ovarian cancer patients. , 2002, Gynecologic oncology.

[13]  S. Ding,et al.  Abnormality of the DNA double-strand-break checkpoint/repair genes, ATM, BRCA1 and TP53, in breast cancer is related to tumour grade , 2004, British Journal of Cancer.

[14]  F. Spyratos,et al.  Relationship between c-erbB-2 and other tumor characteristics in breast cancer prognosis. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[15]  Annuska M Glas,et al.  Gene expression profiles of primary breast tumors maintained in distant metastases , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[16]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.

[17]  W. Carney,et al.  Serum HER-2/neu and response to the aromatase inhibitor letrozole versus tamoxifen. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  Osborne Ck,et al.  Tamoxifen in the Treatment of Breast Cancer , 1998 .

[19]  Carsten O. Peterson,et al.  Estrogen receptor status in breast cancer is associated with remarkably distinct gene expression patterns. , 2001, Cancer research.

[20]  J. Foekens,et al.  Aging of stromal-derived human breast fibroblasts might contribute to breast cancer progression , 2003, Thrombosis and Haemostasis.

[21]  佐治 重衡,et al.  What's going on 乳癌 A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. Ma XJ, Wang Z, Ryan PD, Isakoff SJ, Barmettler A, Fuller A, et al. Cancer Cell. 2004;5:607-16. PMID:15193263--術後補助療法におけるタモキシフェンへの反応性は2つの遺伝子レベルの測定によって予測しうることを示した論文 , 2005 .

[22]  Wei Wang,et al.  A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. , 2004, Cancer cell.

[23]  M. Macleod,et al.  Effects of estrogen on global gene expression: identification of novel targets of estrogen action. , 2000, Cancer research.

[24]  S. Dudoit,et al.  Normalization for cDNA microarray data: a robust composite method addressing single and multiple slide systematic variation. , 2002, Nucleic acids research.

[25]  B Angus,et al.  Expression of c-erbB-2 oncoprotein: a prognostic indicator in human breast cancer. , 1989, Cancer research.

[26]  Alan Mackay,et al.  Expression profiling of purified normal human luminal and myoepithelial breast cells: identification of novel prognostic markers for breast cancer. , 2004, Cancer research.

[27]  D. Hayes.  Tamoxifen: Dr. Jekyll and Mr. Hyde? , 2004, Journal of the National Cancer Institute.

[28]  E. Dougherty,et al.  Gene-expression profiles in hereditary breast cancer. , 2001, The New England journal of medicine.

[29]  T. H. van der Kwast,et al.  High tumor levels of vascular endothelial growth factor predict poor response to systemic therapy in advanced breast cancer. , 2001, Cancer research.

[30]  Barry Komm,et al.  Profiling of estrogen up- and down-regulated gene expression in human breast cancer cells: insights into gene networks and pathways underlying estrogenic control of proliferation and cell phenotype. , 2003, Endocrinology.

[31]  Yudong D. He,et al.  Gene expression profiling predicts clinical outcome of breast cancer , 2002, Nature.

[32]  J. Stec,et al.  Gene expression profiles obtained from fine-needle aspirations of breast cancer reliably identify routine prognostic markers and reveal large-scale molecular differences between estrogen-negative and estrogen-positive tumors. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[33]  R. Osborne,et al.  A genome-wide map showing common regions of loss of heterozygosity/allelic imbalance in breast cancer. , 2000, Cancer research.

[34]  Vladimir B. Bajic,et al.  ERGDB: Estrogen Responsive Genes Database , 2004, Nucleic Acids Res..